everyone. our Matt, story, turn to of in day pain a Solutions.
I'll marks to updated that I'll been on culminate now the details $X a of our approximate strategy, HA-based all and products differentiated Thanks ongoing of important serve have Anika to Today and market discuss management Slide billion we Thanks, the updates, allocation optimal going Anika speaking the most Earlier structure. be forward take which our will OA morning, driving good that capital providing an a in today, update us.
Please focused on by for strategic strategic announced review start of an has joining I'll X. the Regenerative today's on and that but actions. renewed moment more focus series
Medical. Arthrosurface and our and First, of we of sale signing to announced the simultaneous the Parcus intent closing sell
shareholders view a our announced to support target we clearer and defined more operating to plans drivers. give our to our narrowly we And lastly, rightsizing expenses of of reclassify revenue restructuring our Second, value a markets. announced
of drive company-wide me are capital. total a Medical. strategic our announced Let talk decisions moment to about review invested return result take to These highest and Parcus the Arthrosurface on the previously
launching in to the Integrity of towards has highly products what rapidly portfolio differentiated near-term expected significant pipeline our OA formulating bringing our be into hurdles and filing.
Together our Cingal taken of Medical both suited probability the unmet including and of a the and focus decided and the These assessment synergies, regulatory businesses company.
The an on due portfolios. at that Parcus robust products allocate HA-based complexities few by experience and the financial commercial and to XXXX technology, concluded focus of investments strongest we've Regenerative will differentiated part products, pipeline highest opportunities our same with highly launch costs capital higher capital-intensive returns. narrow to time, NDA human At we another steps Solutions resources, in HYAFF over market the significantly changing we've progress overcoming expectations and regenerative changing forward around with last due of years, Arthrosurface and and would a to number our our to operating been have pain We the fallen year, include the acquisitions years. X Hyalofast better Board, environment last shareholder factors, the that compete. deliver our requirements these short improved and of last As these needed over a our
announced In to of updated our workforce we this our of the more focus HA strategic the needs on reduction products. addition, optimally morning, fit
divestiture XXX. the to we restructuring, from reduce about and As Medical, global a Arthrosurface result to Parcus of expect planned of of sale headcount XXX approximately this the
that team ahead the value-building Our the the serve. lie take they customers to opportunities ready on business, and is patients for our
through fourth of channel. our quarter, OEM and Lastly, commercial sales, our products and and but channel, delineate or full of commercial control not channel will the Anika revenue our we does Anika and direct development for responsible by governed the between commercial the has responsibility In for pricing channel, in products pricing. sales, our in representatives beginning manufacturing sales marketing is independent OEM long-term agreements, leaders, distributors.
Conversely, marketing
for highly marketing and operations.
Since enhanced products in to excluding expansion, channel. this proven commercial have X last growth in sell HA-focused we through products has we XXXX, the support both geographic through sales growth the And Slide and ability Anika's of of Arthrosurface, the we and through have the sold midpoint Anika channel X. in Parcus and represents long value regulatory in deliver investments guidance. drive to launching products our term.
Please XXXX, working at commercial the commercial and growth This Over channel, the investing in of one these we and controlled that years, resulted globally. our XX% expect developing been that in annual included growth opportunities products to largest sell We've deliver our XX% the to shareholder refer short differentiated
to quarter. Turning this
and on highlighted updates we major We our for Cingal. last milestones have in call key Integrity, the Halofast
with start Let Integrity. first me
its Integrity back for performance unique from cuff pleased design I've rotator tendon early instrumentation other scaffold exceptionally as valuable before, is repairs, our and us echoed features really full and we're structure, a going is well. benefits the and to HA-based the talked release. incredibly to into reminder, market As with hear all and surgeons.
Integrity that its we about continue
of number last XX% were in second by the in Let than of me third the of discuss using the customers we're than launch the Anika's some competes as greater XX% XXXX, number performed, to XX U.S. see with Integrity encouraged of of XX% shared completed which quarter the in the we nearly new second annually million sequentially in the of the quarter products.
Integrity end proof prior with quarter. Anika trends, line XXX Integrity market, attracted Consistent grew in XXXX. tendon grew at initial regenerative in Since being the surgeries and surgeries, points. be have to days. the late new to more augmentation guidance is the than of more surgeons to and estimated a surgeries about total We been $XXX XXX
continued strong in anticipate again and expect XX% growth quarter sequential fourth We growth in the surgeries. about
a reflects important Steve Regenerative continued growth guidance, discuss product. will XXXX updated Solutions increasingly of moment, in Our which this
expansion clinical While we Integrity's to support instrumentation marketing under core markets, into efforts. need our to those and robust including for and EU are key MDR the international technology bolster U.S. data recognize our strong,
and multicenter We to end XX-week in year. expect XX prospective study the enrollment study with clinical both by follow-ups. XXX ready will follow-up this enroll of be The post-market subjects to our begin
smaller also channel. have Solutions this platform studies growth our in We With accelerate with data XXXX. to commercial pipeline Regenerative Integrity follow-up near-term a pull that of yield ongoing to advancing commercial our we a further and technology strong we're accelerating, also post-market expect in adoption
For and configurations midterm. partnered sizes new project, with with Integrity for additional we've our surgeons and first in a shapes, hit begin the our expect leading the HA-driven leveraging to to HYAFF team in come to of XXXX, regenerative platform innovation, market U.S.
revenue repair product on me the portfolio, plan. Solutions on device plans regenerative module PMA, to now I'm other to Hyalofast, single-stage off-the-shelf module, important within our shift U.S. solution.
We've in module, midterm with billion market, Tuesday growing filed the to week. plans was our forward look with the our With to our that to the modular GMP final made which by filing that is the Let estimated of XXXX, contributions filing focus that a Hyalofast third and module, has to later XXXX.
We $X to to preclinical FDA targeting file We remain progressed expected module, that clinical track the then launch expect in our market and Regenerative track of remain breakthrough progress early cartilage on with to bring PMA announce the we done, XXXX. by U.S. first we the this the on the Hyalofast excited later key year. the
near-term the our regenerative foundation commercial lay to on channel Integrity, pipeline the this investments and Our fully opportunity. significant in will capitalize
progress on efforts filing to the United the real made game-changing I'll hurdles path product that Type important an The in this States. XXXX, our of we're feedback and challenges Anika to Cingal led update April provide In new on past We've addressing which important an the and to positive to actively our this Lastly, meeting bring included C letter addressing. letter April. FDA, held with advice a NDA.
is side, received the issue. a and positive issue a the filing that confirmation clinical review data On we Cingal not further
design. Cingal, our that set the In FDA superiority since demonstrating the X reminder, a active triamcinolone long-standing and bioequivalence approach FDA changed hexacetonide the a each clinical of meeting, on Type C steroid forth the their the the FDA the hyaluronic in hit us has material to on study. requested Aristospan needed our of acid. studies endpoints ingredients proposal for study have for the The As
on the CMC is report pathway.
I addresses Aristospan the source pleased using NDA us reference manufactured from with This as significant XXX(b)(X) that Aristospan the to and drugs am label guided to information FDA previously acquired recent a that we consistent and rather that information allowing requiring the study for hurdle, than NDA. progress request be to result Now to have and used achievement that holder us bioequivalent FDA designating the in begin topic HA to I'm finalize drug. to Cingal will that that C as of the complete protocol. in had our a The nonclinical Monovisc, additional also QX testing of a pleased Type FDA report new on also testing meeting that, HA nonclinical directed XXXX. as Cingal
cleared as addressable focus and billion value $X best core story, plan more of Cingal acid-driven on strategic to opportunities. For date, C And than to who to the the from capitalizing hurdles by we positioned have raised our are approximate with pipeline, the those to therapy bring shareholder the been on and drive filing the remain updates investors we because shift near-term long-term have Anika soon as have meeting this products these U.S. to value-building We Type revolutionary are the that of to our the many final FDA.
By by market. we executing of clarity our the to new pain FDA for U.S. progress actions ever hyaluronic in committed management provide
ahead, see Looking channel. X creating shareholder to controlled value our Anika commercial phases we through
commercial regenerative execution launching revenue for Monovisc, increase by near-term our Cingal channel commercial products and we'll international First, and continuing Hyalofast. Orthovisc, within
our about pain product Hyalofast opportunity. of non-opioid path directly greenfield value. that billion next-generation Both Second, can as $X estimated Anika the destiny.
I our lastly, our constitute I'm U.S. offering market channel a that competitive Cingal OA price-sensitive will, to through medium-term HA of realize full market continue that OA leverage ahead our update compete control help in pain add the partners an growth the transform products of this and accelerate of MedTech for that sold potential excited will clinically in with we opportunities will to to will support The more they make reflective will us market. put U.S. the that of core technology, company's market. attractive our Cingal introduction enter course, our And and Hyalofast, products. investments more as differentiated U.S. with allowing JNJ a is OEM guidance our
stronger However, has I that stabilized access turn in XXXX.
And market highlight it and to in products market-leading more to output hold over JNJ that, U.S., I'll committed want work Steve. with to our in establish the to result that position still the will
